Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01613768 · ClinicalTrials.gov registry record · Phase 2
Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer
A Phase 2 study of Recurrent Salivary Gland Cancer and Stage IVA Salivary Gland Cancer, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT01613768: Completed Phase 2 study of Recurrent Salivary Gland Cancer and Stage IVA Salivary Gland Cancer, sponsored by University of Washington.
NCT01613768 is a Phase 2 study of Recurrent Salivary Gland Cancer and Stage IVA Salivary Gland Cancer that has completed, run by University of Washington. The registered enrollment target is 29 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01613768, a Phase 2 study of Recurrent Salivary Gland Cancer and Stage IVA Salivary Gland Cancer, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
Researchers are doing a research study to examine the use of eribulin (eribulin mesylate) in patients with salivary gland cancer. Researchers want to know if eribulin is safe and effective in treating salivary gland cancer.
Primary Outcome
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by either CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR, summarized using frequencies and percentages.
Conditions Studied
Interventions
- DRUG eribulin mesylate
Study Locations (1)
Washington
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2012-05-08 |
| Est. Completion | 2017-08-23 |
| Phase | Phase 2 |
What the finished NCT01613768 record still lists
NCT01613768 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower).
The record links to 4 conditions, with Recurrent Salivary Gland Cancer appearing as the primary indexed condition, and to 1 intervention - of which eribulin mesylate is the first listed.
NCT01613768 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT01613768 about?
NCT01613768 is a clinical study titled "Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer". Researchers are doing a research study to examine the use of eribulin (eribulin mesylate) in patients with salivary gland cancer. Researchers want to know if eribulin is safe and effective in treating salivary gland cancer.
What is the current status of trial NCT01613768?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2012-05-08. Estimated completion is 2017-08-23.
What conditions does trial NCT01613768 study?
This clinical trial studies the following conditions: Recurrent Salivary Gland Cancer, Stage IVA Salivary Gland Cancer, Stage IVB Salivary Gland Cancer, Stage IVC Salivary Gland Cancer.
What interventions are being tested in trial NCT01613768?
The interventions under investigation include: eribulin mesylate (DRUG).
Who is sponsoring clinical trial NCT01613768?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01613768 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Salivary Gland Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01613768's enrollment target sits among peer trials
29 1669th of 2000 higher than 324 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI